TY - JOUR
T1 - Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery
AU - Díez Valle, R.
AU - Galván, J.
AU - Slof, J.
PY - 2015/4
Y1 - 2015/4
N2 - © 2013 Sociedad Española de Neurología. Objective: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. Material and methods: Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study. Results: Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust. Conclusion: Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
AB - © 2013 Sociedad Española de Neurología. Objective: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. Material and methods: Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study. Results: Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust. Conclusion: Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
KW - Malignant glioma
KW - Fluorescence-guided surgery
KW - Glioblastoma
KW - 5-aminolevulinic acid
KW - Cost-effectiveness
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=5006062
UR - https://www.scopus.com/pages/publications/84925166510
U2 - 10.1016/j.nrl.2013.11.002
DO - 10.1016/j.nrl.2013.11.002
M3 - Article
SN - 0213-4853
VL - 30
SP - 163
EP - 168
JO - Neurologia
JF - Neurologia
IS - 3
ER -
